Q3 EPS Estimate for Axsome Therapeutics Reduced by Analyst

Axsome Therapeutics, Inc. (NASDAQ:AXSM) – Investment analysts at HC Wainwright lowered their Q3 2026 earnings per share estimates for shares of Axsome Therapeutics in a research report issued to clients and investors on Monday, August 24th. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings per share of ($0.95) for the quarter, down from their prior forecast of ($0.91). HC Wainwright has a “Buy” rating on the stock. The consensus estimate for Axsome Therapeutics’ current full-year earnings is ($2.78) per share. HC Wainwright also issued estimates for Axsome Therapeutics’ Q4 2026 earnings at ($0.91) EPS, FY2026 earnings at ($4.10) EPS, Q1 2027 earnings at ($0.27) EPS, Q2 2027 earnings at $1.06 EPS, Q3 2027 earnings at $1.92 EPS and FY2027 earnings at $5.25 EPS.

Axsome Therapeutics (NASDAQ:AXSM) last issued its quarterly earnings data on Monday, August 10th. The company reported ($0.99) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.89) by ($0.10). The firm had revenue of $218.38 million during the quarter, compared to analysts’ expectations of $221.11 million. Axsome Therapeutics had a negative net margin of 24.68% and a negative return on equity of 265.55%.

Other research analysts have also issued reports about the stock. Cantor Fitzgerald restated an “overweight” rating and issued a $272.00 price objective on shares of Axsome Therapeutics in a research note on Monday, May 4th. Morgan Stanley raised their price target on Axsome Therapeutics from $242.00 to $251.00 and gave the stock an “equal weight” rating in a report on Tuesday, August 11th. Mizuho lifted their target price on Axsome Therapeutics from $306.00 to $316.00 and gave the company an “outperform” rating in a research note on Wednesday, August 12th. UBS Group restated a “buy” rating on shares of Axsome Therapeutics in a research note on Monday. Finally, Truist Financial raised Axsome Therapeutics to a “strong-buy” rating in a report on Monday, June 15th. Two analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $267.60.

Axsome Therapeutics Stock Up 0.0%

AXSM stock opened at $205.48 on Wednesday. The company has a market cap of $10.76 billion, a price-to-earnings ratio of -54.79 and a beta of 0.65. The company has a fifty day moving average price of $230.24 and a 200 day moving average price of $206.43. The company has a debt-to-equity ratio of 1.52, a current ratio of 1.43 and a quick ratio of 1.34. Axsome Therapeutics has a 12 month low of $112.90 and a 12 month high of $260.19.

Insider Transactions at Axsome Therapeutics

In related news, CEO Herriot Tabuteau sold 4,660 shares of Axsome Therapeutics stock in a transaction on Thursday, August 6th. The stock was sold at an average price of $213.95, for a total transaction of $997,007.00. Following the completion of the transaction, the chief executive officer directly owned 7,229 shares of the company’s stock, valued at approximately $1,546,644.55. The trade was a 39.20% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Roger Jeffs sold 286 shares of the company’s stock in a transaction on Wednesday, June 10th. The shares were sold at an average price of $246.18, for a total value of $70,407.48. Following the completion of the sale, the director directly owned 58,653 shares in the company, valued at $14,439,195.54. This trade represents a 0.49% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last three months, insiders have sold 200,766 shares of company stock valued at $46,685,646. 20.60% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Kemnay Advisory Services Inc. purchased a new stake in Axsome Therapeutics in the 4th quarter valued at approximately $31,000. Hollencrest Capital Management increased its position in Axsome Therapeutics by 400.0% during the first quarter. Hollencrest Capital Management now owns 200 shares of the company’s stock worth $34,000 after buying an additional 160 shares in the last quarter. Ameriflex Group Inc. acquired a new position in shares of Axsome Therapeutics in the fourth quarter worth $37,000. ABS Investment Management LLC purchased a new position in Axsome Therapeutics in the 2nd quarter valued at about $171,339,000. Finally, Silvant Capital Management LLC purchased a new position in Axsome Therapeutics in the 2nd quarter valued at about $66,000. 81.49% of the stock is currently owned by institutional investors and hedge funds.

More Axsome Therapeutics News

Here are the key news stories impacting Axsome Therapeutics this week:

• Positive Sentiment: HC Wainwright reaffirmed its Buy rating on Axsome Therapeutics, indicating that the firm remains constructive on the company’s longer-term outlook. The analyst still forecasts positive earnings for 2027, including $5.25 per share for the full year. Axsome Therapeutics analyst information
• Neutral Sentiment: HC Wainwright’s revised forecast continues to show Axsome Therapeutics transitioning from losses in 2026 to profitability in 2027, with estimated 2026 EPS of $(4.10), first-quarter 2027 EPS of $(0.27), and positive EPS in the second and third quarters of 2027.
• Negative Sentiment: HC Wainwright reduced its 2026 EPS forecast to $(4.10) from $(3.89), and cut estimates for third- and fourth-quarter 2026 EPS to $(0.95) and $(0.91), respectively. These revisions point to deeper near-term losses.
• Negative Sentiment: The analyst also lowered projected 2027 earnings: second-quarter EPS fell to $1.06 from $1.30, third-quarter EPS to $1.92 from $2.30, fourth-quarter EPS to $2.53 from $2.81, and full-year EPS to $5.25 from $6.47. The downward revisions may pressure the stock because they reduce expectations for the pace of Axsome’s earnings ramp.
• Neutral Sentiment: A separate short-interest report listed zero shares sold short and a zero-day short-interest ratio, but the data appears unreliable because it also reported an undefined percentage change. It therefore provides little actionable insight into AXSM’s trading outlook.

About Axsome Therapeutics

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.

Axsome’s pipeline includes several late-stage and approved product candidates.